ArticleBreast cancer research and treatment2024

Disparities in PI3K/mTOR inhibitor use, toxicities, and outcomes among patients with metastatic breast cancer.

Claire Sathe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.